Compound of hepatitis B virus antigen and lewis oligosaccharide and preparation method and application thereof

Abstract

The invention discloses a compound of a hepatitis B virus antigen and lewis oligosaccharide and a preparation method and application thereof. The compound is prepared mainly through combination of a core hepatitis B virus antigen and lewis oligosaccharides-x. The preparation method comprises the following steps: preparing a conjugate of the core hepatitis B virus antigen and streptavidin, and combining the conjugate with (lewis oligosaccharides-x)-sodium polyacrylate-biotin through high affinity of the streptavidin and the biotin, thereby preparing the compound of the hepatitis B virus antigen and the lewis oligosaccharide. The compound enhances the capability of recognition of a immune system to the hepatitis B virus due to the active targeting of dendritic cells through the high affinity of the lewis oligosaccharides-x and DC-SIGN, can activate specific CTL responses and induce strong anti-viral immunity, and can be applied in the preparation of vaccines for treatment of the hepatitis B.

Description

technical field [0001] The invention relates to a compound of protein and oligosaccharide, in particular to a compound of hepatitis B virus antigen and Lewis oligosaccharide, and also relates to a preparation method and application of the compound. Background technique [0002] Hepatitis B virus (HBV) is a hepatotropic DNA virus. Hepatitis B viral hepatitis B, referred to as hepatitis B, is caused by hepatitis B virus, mainly through blood, body fluids and mother-to-child transmission, and has a chronic carrier state of infectious diseases. At present, more than 300 million people in the world are infected with chronic hepatitis B virus, about half of which are in my country. This kind of infection easily develops into chronic hepatitis and liver cirrhosis, and a small number of cases can be transformed into primary hepatocellular carcinoma, which is the ninth cause of death among human diseases announced by the World Health Organization. For this reason, seeking an ideal ...

AI Technical Summary

Problems solved by technology

The in vivo method is to directly target dendritic cells with protein, polypeptide or gene vaccines in vivo, which is simpler and easier for clinical operation, but it has the following problems: most of the protein vaccines studied in the past use Fc expressed by dendritic cells. Receptors, complement receptors, mannose receptors, CD40 or B7 are targeted receptors, but these receptors are also expressed on blood cells, thus lacking in specific targeting of dendritic cells; genetic vaccines are mostly used Viral vectors with a high transfection rate, but most viral vectors cannot specifically target dendritic cells, and the viral vectors themselves may express a large number of immunogenic proteins, which will not only interfere with the immune effect of the target gene, but also It may cause the viral vector containing the target gene to be quickly cleared by the body. In addition, biological safety is also an inherent defect of the viral vector

Images